• LAST PRICE
    2.5700
  • TODAY'S CHANGE (%)
    Trending Down-0.1700 (-6.2044%)
  • Bid / Lots
    1.5300/ 3
  • Ask / Lots
    2.6000/ 3
  • Open / Previous Close
    2.8300 / 2.7400
  • Day Range
    Low 2.5200
    High 2.8300
  • 52 Week Range
    Low 2.0700
    High 9.7100
  • Volume
    41,430
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.74
TimeVolumeFSTX
09:32 ET74582.8199
09:36 ET8002.82
09:38 ET23752.83
09:39 ET3002.78
09:41 ET17002.74
09:45 ET11002.69
09:56 ET4002.75
09:57 ET11002.69
10:01 ET1002.66
10:12 ET38002.6799
10:37 ET3002.645
10:39 ET1002.6136
10:42 ET3002.6542
10:44 ET3992.64
10:50 ET4002.605
10:51 ET3002.605
10:53 ET3002.605
10:55 ET5412.5802
10:57 ET3002.5987
11:08 ET1002.58
11:11 ET2332.55
11:18 ET3002.5741
11:42 ET6002.55
11:45 ET17792.57
11:47 ET4002.56
11:51 ET4702.5897
11:58 ET2002.6
12:09 ET1002.6099
12:23 ET4602.61
12:41 ET1002.6057
01:15 ET1002.62
02:47 ET2002.561
02:56 ET9242.555
03:00 ET6002.55
03:07 ET7002.5658
03:20 ET2002.5212
03:38 ET6002.54
03:39 ET2502.57
03:48 ET8002.577
03:50 ET8002.565
03:52 ET1002.55
03:56 ET1002.55
03:57 ET3002.55
03:59 ET5182.57
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesFSTX
F-Star Therapeutics Inc
59.1M
-2.2x
---
United StatesMDWD
Mediwound Ltd
59.5M
-3.3x
---
United StatesCDAK
Codiak BioSciences, Inc.
64.8M
-1.8x
---
United StatesICCC
ImmuCell Corp
65.4M
60.2x
---
United StatesMEIP
MEI Pharma Inc
60.2M
-0.9x
---
United StatesHARP
Harpoon Therapeutics Inc
70.8M
-0.9x
---
As of 2022-05-24

Company Information

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing next-generation immunotherapies to transform the lives of patients with cancer. The Company's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.

Contact Information

Headquarters
B920 Babraham Research Campus Babraham Research CampusCAMBRIDGE, MA, United Kingdom CB22 3AT
Phone
122-349-7400
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Nessan Bermingham
President, Chief Executive Officer, Director
Eliot Forster
Chief Financial Officer, Treasurer, Secretary
Darlene Deptula-Hicks
Chief Scientific Officer
Neil Brewis
Chief Medical Officer
Louis Kayitalire

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$59.1M
Revenue (TTM)
$20.8M
Shares Outstanding
21.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.80
EPS
$-1.19
Book Value
$4.64
P/E Ratio
-2.2x
Price/Sales (TTM)
2.8
Price/Cash Flow (TTM)
---
Operating Margin
-149.62%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.